Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F19%3A10394406" target="_blank" >RIV/00064203:_____/19:10394406 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/19:10394406
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=cIPhj-DSzL" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=cIPhj-DSzL</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/pedi.12833" target="_blank" >10.1111/pedi.12833</a>
Alternative languages
Result language
angličtina
Original language name
Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective
Original language description
BackgroundFrequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. MethodsThe study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. ResultsWe collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. ConclusionsAlthough innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pediatric Diabetes
ISSN
1399-543X
e-ISSN
—
Volume of the periodical
20
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
434-443
UT code for WoS article
000468283100009
EID of the result in the Scopus database
2-s2.0-85064480397